PRPO logo.png
Precipio Commences Validation Study of Proprietary IV-Cell Cytogenetics Media at University of Pennsylvania
22 janv. 2018 08h27 HE | Precipio, Inc.
NEW HAVEN, Conn., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics firm Precipio, Inc. (NASDAQ:PRPO), today announced it is collaborating with the cytogenetics laboratory at the University of...